This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AZ&Me™ Prescription Savings Program For People With Medicare Part D Removes Out-of-Pocket Spend Requirement

AstraZeneca (NYSE:AZN) today announced that it is simplifying the enrollment process for the AZ&Me™ Prescription Savings Program for people with Medicare Part D by removing an out-of-pocket spend requirement.

As of Jan. 1, the program will no longer require that people with Medicare prescription drug coverage spend 3 percent of their annual household income on out-of-pocket costs for prescription medicines within the calendar year to qualify.

Those who meet all of the other program eligibility requirements may begin receiving their AstraZeneca medicines for free upon successfully completing the enrollment process. To be eligible for the program, a Medicare beneficiary must:

  • Be enrolled in Medicare Part D.
  • Have an annual household income at or below $35,000 for individuals or $48,000 for couples.
  • Not be enrolled in the Medicare Limited Income Subsidy.

"We regularly evaluate how we can simplify our program enrollment process and saw an opportunity to do so for people with Medicare prescription drug coverage," said Jennifer McGovern, Director, AZ&Me Prescription Savings Programs. "Removing the out-of-pocket spend requirement means that people will no longer have to gather documentation from their pharmacy before completing their enrollment, saving them time and helping them get their AstraZeneca medicines sooner."

AstraZeneca has offered prescription savings programs for 34 years and offers one of the industry’s most generous programs. The company will continue to make program enhancements that better serve patients and the advocates who help them.

"Prescription assistance programs help fill an important need for many people who have Medicare Part D coverage, but may not be able to access all of their medicines because of limited financial resources," said Nora Dowd Eisenhower, senior vice president for economic security and director of the Center for Benefits Access, National Council on Aging. "We salute AstraZeneca for its continued leadership in patient assistance and will use this opportunity to remind Medicare beneficiaries, caregivers and advocates that these kinds of programs are a helpful resource for many who don’t qualify for extra help through the Medicare Limited Income Subsidy."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs